JAK2 and breast cancer: In summary, the prolactin-Jak2-Stat5 pathway, which may suppress breast cancer cell epithelial-to-mesenchymal transition, invasion and drug resistance [21-23], is potently and selectively suppressed by extracellular tumor acidosis.